Ms Gallaher finished up in her role on 1 April and an interim CEO will be appointed while recruitment of a permanent replacement is underway.

Cerulea Clinical Trials Chair Professor Keith Martin thanked Michelle Gallaher for her contribution since taking on the role in February 2024.

“During her time as Cerulea’s inaugural CEO, Michelle has led important foundational work to position our new clinical trials centre for success,’’ said Professor Martin.

“I wish her all the very best for her next endeavour.”

Michelle Gallaher thanked the many people who had supported the establishment of Cerulea.

“I’m grateful for the support of industry sponsors and clinicians who have collaborated with Cerulea to deliver high quality clinical research – and to the people living with eye disease who have volunteered to take part in clinical trials,’’ she said.

“It has been a privilege to lead a team of passionate and dedicated clinical trial professionals at Cerulea and establish a centre which will increase community access to sight-saving research.”

Sponsor inquiries about current or future clinical trials at Cerulea can be directed to Chief Clinical Operations Officer Marios Constantinou at mconstantinou@ceruleaclinicaltrials.org.au